Therapy Areas

Established leaders in the GI therapeutic area, our PPI (Proton Pump Inhibitor) nbrands have shaped the market landscape in India. Market leaders in the Omeprazole and Rabeprazole category, the Omez (Omeprazole) and Razo (Rabeprazole) franchise feature in the Top-300 of the Indian Pharma Market(IPM).

Econorm (Saccharomyces Boulardii), a globally preferred probiotic is marketed in India exclusively by us, as preferred partners of Biocodex, the French innovator company. Addressing the diarrhea disease burden in India, Econorm features in the Top-300 of IPM.

More recently, we have forayed into the Hepatology super-specialty segment, increasing awareness about the disease and serving the needs of millions of hepatitis B patients in India. Our brands Entaliv (Entecavir) and Reviro (Tenofovir) are economical, first line of treatment options.

Click here to view the complete portfolio.

Cancer is a disease that requires specialized treatment and care at every stage. Our understanding of this fact can be seen in our broad range of high-quality cancer care medications. Across the spectrum of cytotoxics, targeted therapies and supportive care, our range is designed to effectively combat cancer and the side effects associated with the therapy. Grafeel (Filgrastim injection), world’s first recombinant human GCSF biosimilar protein in the field of cancer and Reditux (Rituximab injection), world's first bio-similar therapeutic monoclonal antibody have shaped the treatment landscape in India. Peggrafeel (Pegfilgrastim injection), world’s only single source pegfilgrastim is a market leader in the segment.

Click here to view the complete portfolio.

Our pain management portfolio addresses a whole spectrum of pain conditions.

Launched in 1995, Nise (Nimesulide), our legendary pain brand set a benchmark in its category. It features in the Top-300 of the Indian Pharma Market(IPM).

Launched in 1991, the Ketorol (Ketorolac) franchisee is the most prescribed dental pain management brand in India.

Durolane (Hyaluronic Acid) is our differentiated launch in the pain management portfolio. A single injection treatment to relieve the pain of knee or hip osteoarthritis, Durolane was launched in an exclusive partnership with Smith & Nephew. It is based upon a natural, safe and proven technology called NASHA (Non-Animal Stabilised Hyaluronic Acid).

Click here to view the complete portfolio.

India is experiencing a surge in the incidence of cardiovascular diseases. Addressing the increasing disease burden, we have built major brands – Stamlo (Amlodipine) and Stamlo Beta (Amlodipine + Atenolol), both of which feature in the Top-300 of the Indian Pharma Market (IPM). We were the first ones to enter the (Angiotensin Converting Enzyme) inhibitor market in 1989 with the launch of Enam (Enalapril).

Since compliance is critical to BP control, we have introduced Activ range (monthly pack) for our prominent hypertension brands - Atocor (Atorvastatin) and Telsartan (Telmisartan). An innovative packaging concept, it helps in driving adherence to therapy.

Optidoz is our low dose combination of three anti-hypertensive drugs (Amlodipine 2.5 mg, Telmisartan 20 mg and Hydrochlorothiazide 6.25 mg) in a single pill. A first-of-its-kind approach to hypertension therapy, Optidoz controls hypertension with reduced side effects. The pill has simplified the traditional step-care treatment approach clinicians typically follow for hypertension management.

Click here to view the complete portfolio.

Experiencing rapid urbanization, demographic transition and lifestyle modifications, diabetes has reached epidemic proportions in India. It is a chronic condition in which adherence to therapy is very critical.

Fulfilling the unmet need for a patient-friendly dosage form, small enough to enable easy swallowing, Metsmall (Metformin Hydrochloride Sustained Release Tablet 500 mg and 1000 mg) is our differentiated offering in the diabetes portfolio. A smaller size pill than the conventional, much larger Metformin, Metsmall is a unique innovation that delivers the same efficacy or bioequivalence.

The Glimy (Glimepride) franchise is also steadily growing, and is one of the top three Glimeprides selling in India. Consolidating our diabetes portfolio are other critical brands such as Reclide (Gliclazide) and Reclimet (Gliclazide+Metformin).

Click here to view the complete portfolio.

Factors such as appearance consciousness, high incidence of skin diseases and increasing disposable incomes are driving people to seek appropriate medical solutions for hair and skin related disorders. The dermatology market in India is growing fast, and we are trying to keep pace.

Minoxidil is the most preferred molecule amongst dermatologists for treatment of androgenetic alopecia. Mintop – our Minoxidil brand is a segment leader in the category. It also features in the Top-300 of the Indian Pharma Market (IPM). More recently we have launched a foam formulation of minoxidil for patient convenience / ease of application. Supportive therapy products such as Revilus add up to the hair loss portfolio.

A consumer-pull driven product, the Venusia range is our signature brand in the emollient market. The extensive range including moisturizer, lotion, intense moisturizer and bathing bar provides an end-to-end moisturizing solution.

Addressing a significant under-met patient need, we have in-licensed Melgain lotion (Decapeptide) for the treatment of vitiligo.

Click here to view the complete portfolio.

Within the dental segment, we have a significant share in the Indian stomatological market.

Offering a range of specifically formulated toothpastes to combat dental sensitivity, Senquel-F and Vantej are our popular brands in the segment. While Senquel – F is the most preferred brand in its category, Vantej is a differentiated offering based on patented NovaMin technology. We are one of the few pharma corporates in India, marketing such a product.

Click here to view the complete portfolio.

Our Nephrology portfolio is characterized by Cresp - the first generic Darbepoetin Alfa in the world. The biosimilar was developed in-house, in line with our purpose of providing affordable and innovative medicines. A convenient and affordable dosage, the product addresses patient compliance need.

Click here to view the complete portfolio.

Advancing age is associated with higher incidence of common urological ailments such as Benign Prostatic Hyperplasia (BPH), prostate cancer, calculi and urinary incontinence. With increasing life expectancy in India, the urological disease burden is also expected to increase.

Addressing such an impending need, we have pioneered 5-Alpha Reductase Inhibitors – Dutas (Dutasteride) franchisee - for the medical management of BPH, shaping the market landscape. We have in-licensed Pamorelin (Triptorelin Pamoate) from Debio Pharm Group, Switzerland for palliative treatment of advanced prostate cancer.

Click here to view the complete portfolio.